CO5011105A1 - ORGANIC COMPOUNDS TO TREAT OBESITY AND RELATED DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESSES FOR THEIR PREPARATION - Google Patents

ORGANIC COMPOUNDS TO TREAT OBESITY AND RELATED DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESSES FOR THEIR PREPARATION

Info

Publication number
CO5011105A1
CO5011105A1 CO98075202A CO98075202A CO5011105A1 CO 5011105 A1 CO5011105 A1 CO 5011105A1 CO 98075202 A CO98075202 A CO 98075202A CO 98075202 A CO98075202 A CO 98075202A CO 5011105 A1 CO5011105 A1 CO 5011105A1
Authority
CO
Colombia
Prior art keywords
carbon atoms
atoms
carbon
alkoxy
alkyl
Prior art date
Application number
CO98075202A
Other languages
Spanish (es)
Inventor
Peter Buehlmayer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5011105A1 publication Critical patent/CO5011105A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con un compuesto de lafórmula I: donde X es S ó NH, e Y y Z son cada uno CH; o X es NH, es una de las variables Y y Z es N, y la otra es CH; R1 y R2 , independientemente uno del otro, representan hidrógeno, alquilo de 1 a 7 átomos de carbono, o alquilo de 1 a 7 átomos de carbono sustituido por hidroxi, halógeno, alcoxi de 1 a 7 átomos de carbono, carboxi, alcoxi, de 1 a 7 átomos de carbono-carbonilo, carbamoílo, alquilo de 1 a 7 átomos de carbono-carbamoílo, dialquilo de 1 a 7 átomos de carbono-carbamoílo, cicloalquilo de 3 a 8 átomos de carbono, por cicloalquilo de 3 a 8 átomos de carbono que está sustituido por alcoxi de 1 a 7 átomos de carbono-carbonilo, o representan alcanoílo de 2 a 7 átomos de carbono; mientras que cuando menos una de las variables R1 y R2 es diferente de hidrógeno; o el grupo NR1 R2 alquileno de 2 a 6 átomos de carbono-amino lineal que está insustituido a sustituido por alquilo de 1 a 7 átomos de carbono, hidroxialquilo de 1 a 7 átomos de carbono, alcoxi de 1 a 7 átomos de carbono, alcoxi de 1 a 7 átomos de carbono, alcoxi de 1 a 7 átomos de carbono-alcoxi de 1 a 7 átomos de carbono-alquilo de 1 a 7 átomos de carbono, tioalquilo de 1 a 7 átomos de carbono-alquilo de 1 a 7 átomos de carbono, alcano 1 a 7 átomos de carbono, alcano de 1 a 7 átomos de carbono-sulfonialquilo de 1 a 7 átomos de carbono, aminoalquilo de 1 a 7 átomos de carbono, alquilo de 1 a 7 átomos de carbono-aminoalquilo de 1 a 7 átomos de carbono, dialquilo de 1 a 7 átomos de carbono-aminoalquilo de 1 a 7 átomos de carbono, hidroxi, ciano, amino, alquilo de 1 a 7 átomos de carbono-amino, dialquilo de 1 a 7 átomos de carbono-amino, alcanoílo de 1 a 7 átomos de carbono, hidroxiliminoalquilo de 2 a 7 átomos de carbono, carboxi, alcoxi de 1 a 7 átomos de carbono-carbamoílo, dialquilo de 1 a 7 átomos de carbono-carbamoílo, o por oxo, ...The present invention relates to a compound of the formula I: where X is S or NH, and Y and Z are each CH; or X is NH, is one of the variables Y and Z is N, and the other is CH; R1 and R2, independently of each other, represent hydrogen, alkyl of 1 to 7 carbon atoms, or alkyl of 1 to 7 carbon atoms substituted by hydroxy, halogen, alkoxy of 1 to 7 carbon atoms, carboxy, alkoxy, of 1 to 7 carbon-carbonyl atoms, carbamoyl, alkyl of 1 to 7 carbon-carbamoyl atoms, dialkyl of 1 to 7 carbon-carbamoyl atoms, cycloalkyl of 3 to 8 carbon atoms, per cycloalkyl of 3 to 8 atoms of carbon which is substituted by alkoxy of 1 to 7 carbon-carbonyl atoms, or represent alkanoyl of 2 to 7 carbon atoms; while at least one of the variables R1 and R2 is different from hydrogen; or the NR1 R2 alkylene group of 2 to 6 carbon-linear amino atoms which is unsubstituted to substituted by alkyl of 1 to 7 carbon atoms, hydroxyalkyl of 1 to 7 carbon atoms, alkoxy of 1 to 7 carbon atoms, alkoxy from 1 to 7 carbon atoms, alkoxy of 1 to 7 carbon atoms-alkoxy of 1 to 7 carbon atoms-alkyl of 1 to 7 carbon atoms, thioalkyl of 1 to 7 carbon atoms-alkyl of 1 to 7 atoms carbon, alkane 1 to 7 carbon atoms, alkane of 1 to 7 carbon atoms-sulfonyalkyl of 1 to 7 carbon atoms, aminoalkyl of 1 to 7 carbon atoms, alkyl of 1 to 7 carbon atoms-aminoalkyl of 1 at 7 carbon atoms, dialkyl of 1 to 7 carbon-aminoalkyl atoms of 1 to 7 carbon atoms, hydroxy, cyano, amino, alkyl of 1 to 7 carbon-amino atoms, dialkyl of 1 to 7 carbon atoms- amino, alkanoyl of 1 to 7 carbon atoms, hydroxyiminoalkyl of 2 to 7 carbon atoms, carboxy, alkoxy of 1 to 7 carbon atoms o-carbamoyl, dialkyl of 1 to 7 carbon-carbamoyl atoms, or by oxo, ...

CO98075202A 1997-12-22 1998-12-17 ORGANIC COMPOUNDS TO TREAT OBESITY AND RELATED DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESSES FOR THEIR PREPARATION CO5011105A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19757248 1997-12-22

Publications (1)

Publication Number Publication Date
CO5011105A1 true CO5011105A1 (en) 2001-02-28

Family

ID=7853006

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075202A CO5011105A1 (en) 1997-12-22 1998-12-17 ORGANIC COMPOUNDS TO TREAT OBESITY AND RELATED DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESSES FOR THEIR PREPARATION

Country Status (6)

Country Link
AR (1) AR014406A1 (en)
AU (1) AU2415299A (en)
CO (1) CO5011105A1 (en)
PE (1) PE20000127A1 (en)
WO (1) WO1999032466A1 (en)
ZA (1) ZA9811705B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756797B2 (en) 1998-11-10 2003-01-23 Banyu Pharmaceutical Co., Ltd. Spiro-indolines as Y5 receptor antagonists
FR2792314B1 (en) * 1999-04-15 2001-06-01 Adir NOVEL AMINOTRIAZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
CA2371274A1 (en) * 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
SI2014285T1 (en) * 1999-11-26 2010-08-31 Shionogi & Co NPYY5 antagonists
ES2317889T3 (en) * 2000-03-01 2009-05-01 Janssen Pharmaceutica Nv DERIVATIVES OF TIAZOLIL 2,4-DISPOSED.
FR2815346B1 (en) * 2000-10-13 2004-02-20 Servier Lab NOVEL AMINOTRIAZOLONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
JP2005508841A (en) * 2001-03-29 2005-04-07 スミスクライン・ビーチャム・コーポレイション Compounds and methods
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2004092146A2 (en) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
EP1620420A2 (en) 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Substituted carboxylic acids
WO2006042215A1 (en) * 2004-10-08 2006-04-20 Janssen Pharmaceutica, N.V. 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
JP2023508909A (en) * 2019-12-20 2023-03-06 イケナ オンコロジー， インコーポレイテッド 4-Phenyl-N-(phenyl)thiazol-2-amine Derivatives and Related Compounds as Aryl Hydrocarbon Receptor (AHR) Agonists, For example, for the Treatment of Angiogenesis-Related Disorders or Inflammatory Diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776765A (en) * 1972-02-28 1973-12-04 Cities Service Co Process for protecting a substrate with an n{11 substituted aminoarylsulfonamide intumescent agent
FR2701480B1 (en) * 1993-02-15 1995-05-24 Sanofi Elf Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them.
AU3201095A (en) * 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation

Also Published As

Publication number Publication date
AR014406A1 (en) 2001-02-28
ZA9811705B (en) 1999-09-07
WO1999032466A1 (en) 1999-07-01
AU2415299A (en) 1999-07-12
PE20000127A1 (en) 2000-03-14

Similar Documents

Publication Publication Date Title
CO5011105A1 (en) ORGANIC COMPOUNDS TO TREAT OBESITY AND RELATED DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESSES FOR THEIR PREPARATION
BR0010555A (en) Neuraminidase Inhibitors
ES2189330T3 (en) HETEROCICLIC DERIVATIVES N6 OF THE SUBSTITUTED ADENOSINE.
BR0111230A (en) Compound, and, use and process for the preparation thereof
CO5011039A1 (en) METALOPROTEASE HYDROXAMATE HYDROXAMATE INHIBITORS REPLACED
BR0213455A (en) Compound, its use, pharmaceutical composition, method for treating or preventing a disease to which an adenosine receptor is related, and method for promoting defecation
CO5580815A2 (en) ADAMANTAN DERIVATIVES, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR0307833A (en) Controlled synthesis of ziprasidone and its compositions
ES2195034T3 (en) METALOPROTEINASE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING THIS INHIBITOR AND ITS PHARMACEUTICAL USE, AND PROCEDURES THAT SERVE FOR PREPARATION.
BR0315913A (en) Flame Retardant Compositions
BR9713465A (en) Cytically substituted amine metallotprotease inhibitors
UY25142A1 (en) CCR-3 RECEPTOR ANTAGONISTS
PE20000339A1 (en) BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS
BR9913654A (en) P-38alpha kinase inhibitors
ES2148715T3 (en) SYNERGETIC MIX OF STABILIZERS.
UY28877A1 (en) METHYL-ARIL OR HETEROARIL-AMIDA SUBSTITUTED COMPOUNDS AND COMPOSITIONS
PT1037886E (en) TRIAZINE ANGIOGENESE INHIBITORS
BR9914696A (en) Compound, process for treating cyclooxygenase-2-mediated disorder in an individual, and pharmaceutical composition
ES2059335T3 (en) DERIVATIVES OF PIRIDO (3,2,1-IJ) -1,3,4-BENZOXADIAZINA, PROCEDURE FOR ITS OBTAINING, CORRESPONDING PHARMACEUTICAL PREPARATIONS AND INTERMEDIATE PRODUCTS USABLE IN THE PROCEDURE.
AR013875A1 (en) COMPOUND 2-IMIDAZOLINILAMINOINDOL, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR007969A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED PYROLES, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS
CR10974A (en) CARBOXIPEPTIDASE B PLASMATIC INHIBITORS (DIVISIONAL)
NO20002589L (en) Bifenylamidinderivater
BR9912556A (en) Triazolpyridines for the treatment of thrombotic disorders
ES2196614T3 (en) ANALOGS OF 1-3-DIHIDROXI-20,20-DIALQUIL-VITAMIN D3.